NORLIQVA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Norliqva, and what generic alternatives are available?
Norliqva is a drug marketed by Cmp Dev Llc and is included in one NDA. There are four patents protecting this drug.
The generic ingredient in NORLIQVA is amlodipine besylate. There are fifty drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the amlodipine besylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norliqva
A generic version of NORLIQVA was approved as amlodipine besylate by COREPHARMA on May 23rd, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NORLIQVA?
- What are the global sales for NORLIQVA?
- What is Average Wholesale Price for NORLIQVA?
Summary for NORLIQVA
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 125 |
| Patent Applications: | 4,620 |
| Drug Prices: | Drug price information for NORLIQVA |
| What excipients (inactive ingredients) are in NORLIQVA? | NORLIQVA excipients list |
| DailyMed Link: | NORLIQVA at DailyMed |
Pharmacology for NORLIQVA
| Drug Class | Dihydropyridine Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists |
US Patents and Regulatory Information for NORLIQVA
NORLIQVA is protected by eleven US patents.
Patents protecting NORLIQVA
Pharmaceutical solution of amlodipine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
Pharmaceutical solution of amlodipine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA
Pharmaceutical solution of amlodipine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE TREATMENT OF CONFIRMED OR SUSPECTED VASOSPASTIC ANGINA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE TREATMENT OF CONFIRMED OR SUSPECTED VASOSPASTIC ANGINA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE TREATMENT OF CONFIRMED OR SUSPECTED VASOSPASTIC ANGINA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
